Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large-Volume Protein Delivery

被引:46
作者
Doughty, Diane V. [1 ]
Clawson, Corbin Z. [1 ]
Lambert, William [1 ]
Subramony, J. Anand [1 ]
机构
[1] MedImmune LLC, Biopharmaceut Dev, Drug Delivery & Device Dev, Gaithersburg, MD 20878 USA
关键词
skin; injectables; injectors; physiological model; biocompatibility; monoclonal antibody; subcutaneous; parenteral; device; pain; IMMUNOGLOBULIN REPLACEMENT; MONOCLONAL-ANTIBODY; PREFILLED SYRINGE; PAIN; THERAPY; PHARMACOKINETICS; TRASTUZUMAB; CHALLENGES; TOXICOLOGY; DURATION;
D O I
10.1016/j.xphs.2016.04.009
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Subcutaneous injection allows for self-administration of monoclonal antibodies using prefilled syringes, autoinjectors, and on-body injector devices. However, subcutaneous injections are typically limited to 1 mL due to concerns of injection pain from volume, viscosity, and formulation characteristics. Back pressure can serve as an indicator for changes in subcutaneous mechanical properties leading to pain during injection. The purpose of this study was to investigate subcutaneous pressures and injection site reactions as a function of injection volume and flow rate. A pressure sensor in the fluid path recorded subcutaneous pressures in the abdomen of Yorkshire swine. The subcutaneous tissue accommodates large-volume injections and with little back pressure as long as low flow rates are used. A 1 mL injection in 10 seconds (360 mL/h flow rate) generated a pressure of 24.0 +/- 3.4 kPa, whereas 10 mL delivered in 10 minutes (60 mL/h flow rate) generated a pressure of 7.4 +/- 7.8 kPa. After the injection, the pressure decays to 0 over several seconds. The subcutaneous pressures and mechanical strain increased with increasing flow rate but not increasing dose volume. These data are useful for the design of injection devices to mitigate back pressure and pain during subcutaneous large-volume injection. (C) 2016 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:2105 / 2113
页数:9
相关论文
共 45 条
[11]   Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices [J].
di Cantogno, Elisabetta Verdun ;
Russell, Susan ;
Snow, Tom .
PATIENT PREFERENCE AND ADHERENCE, 2011, 5 :173-180
[12]   Subcutaneous immunoglobulin therapy for multifocal motor neuropathy [J].
Eftimov, Filip ;
Vermeulen, Marinus ;
de Haan, Rob J. ;
van den Berg, Leonard H. ;
van Schaik, Ivo N. .
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2009, 14 (02) :93-100
[13]  
GARDULF A, 1995, LANCET, V345, P365
[14]   Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies -: A prospective, multi-national study [J].
Gardulf, Ann ;
Nicolay, Uwe ;
Asensio, Oscar ;
Bernatowska, Ewa ;
Boeck, Andreas ;
Costa Carvalho, Beatriz ;
Granert, Carl ;
Haag, Stefan ;
Hernandez, Dolores ;
Kiessling, Peter ;
Kus, Jan ;
Pons, Jaune ;
Niehues, Tim ;
Schmidt, Sigune ;
Schulze, Ilka ;
Borte, Michael .
JOURNAL OF CLINICAL IMMUNOLOGY, 2006, 26 (02) :177-185
[15]   EFFECT OF LOCAL PH ON INTERSTITIAL FLUID PRESSURE [J].
GILANYI, M ;
KOVACH, AGB .
AMERICAN JOURNAL OF PHYSIOLOGY, 1991, 261 (03) :H627-H631
[16]   Developments and Challenges for mAb-Based Therapeutics [J].
Goswami, Sumit ;
Wang, Wei ;
Arakawa, Tsutomu ;
Ohtake, Satoshi .
ANTIBODIES, 2013, 2 (03) :452-500
[17]   Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies [J].
Gustafson, R. ;
Gardulf, A. ;
Hansen, S. ;
Leibl, H. ;
Engl, W. ;
Linden, M. ;
Mueller, A. ;
Hammarstrom, L. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2008, 152 (02) :274-279
[18]   Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency [J].
Hagan, John B. ;
Fasano, Mary B. ;
Spector, Sheldon ;
Wasserman, Richard L. ;
Melamed, Isaac ;
Rojavin, Mikhail A. ;
Zenker, Othmar ;
Orange, Jordan S. .
JOURNAL OF CLINICAL IMMUNOLOGY, 2010, 30 (05) :734-745
[19]   Express subcutaneous IgG infusions: Decreased time of delivery with maintained safety [J].
Hansen, S ;
Gustafson, R ;
Smith, CIE ;
Gardulf, A .
CLINICAL IMMUNOLOGY, 2002, 104 (03) :237-241
[20]   Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial [J].
Heise, T. ;
Nosek, L. ;
Dellweg, S. ;
Zijlstra, E. ;
Praestmark, K. A. ;
Kildegaard, J. ;
Nielsen, G. ;
Sparre, T. .
DIABETES OBESITY & METABOLISM, 2014, 16 (10) :971-976